Latest Breaking News On - Takeda pharmaceutical company limited - Page 1 : comparemela.com

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 rADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura cTTP

Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval under exceptional circumstances of recombinant ADAMTS13 rADAMTS13 for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK (BUSINESS WIRE) Jun 1, 2024

Gold Investment Management Ltd. Makes New $994,000 Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Gold Investment Management Ltd. acquired a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 69,664 shares of the company’s stock, valued at approximately $994,000. A number of other large investors […]

ASKA Pharmaceutical : May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area

Press Release Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area TOKYO, May 31, 2024 -.

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)